Related Articles

• Outcomes of high‑dose methotrexate for CNS prophylaxis in diffuse large B‑cell lymphoma with an intermediate or high CNS‑International Prognostic Index: A single‑center retrospective cohort study
• Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab
• Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study
• miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma
• Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone